The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation

Inclusion criteria

• Signed informed consent obtained before any trial-related activities.
• Men aged >18 and <41 years
• Normal findings in medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
• Normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant

Exclusion criteria

• Known or suspected allergy to trial product or related products (Prasugrel, Clopidogrel, Ticlopidine)
• Known or suspected hereditary problems of galactose intolerance, Lapp lactase deficiency or glucosegalactose malabsorption
• Treatment with an investigational drug within three weeks prior to this trial
• Treatment with a drug (e.g. ketoconazole, omeprazole) that interferes with cytochrome P450, the enzyme responsible for the conversion of prasugrel to its active form, three weeks prior to this trial
• Participation in an LPS trial within the last 6 weeks
• Smoking of more than 5 cigarettes per day
• Hereditary deficiency of protein C or S, or a mutation of FV (Leiden), or any other known abnormality affecting coagulation, fibrinolysis or platelet function
• History of gastro-duodenal ulcera, cardiovascular disease, vasculitis, diabetes mellitus, or hypertension
• History of brain tumor or history of neurosurgery
• Hemorrhagic diathesis, trauma or surgery within last 3 months
• History of hemorrhagic retinopathy
• Hematuria or detection of occult blood in stool sample
• Liver or kidney dysfunction
• Regular use of medication or abuse of alcohol
• Use of any medication within one week prior to the first trial day
• Symptoms of a clinically relevant illness in the 3 weeks before the first trial day
• Excessive sporting activities
• Weight >95kg and <60kg